Fig. 2

Kaplan Meier plots of HTA approval time for multi-indication products, defined as time from regulatory approval to HTA approval. I – HTA approval time of first vs subsequent indications in England. II – HTA approval time of first vs subsequent indications in Scotland. III – HTA approval time of first vs subsequent indications in France. IV – HTA approval time of first vs subsequent indications in Germany. V – HTA approval time of first vs subsequent indications in Canada. VI—HTA approval time of first vs subsequent indications in Australia. Abbreviations: CADTH—Canadian Agency for Drugs and Technologies in Health, G-BA – Federal Joint Committee, HAS – Haute Autorité de Santé (HAS), NICE – National Institute of Health and Care Excellence, PBAC – Pharmaceutical Benefits Advisory Committee, SMC – Scottish Medicines Consortium

p-value calculated based on Log rank tests